Overview
- The companies signed a definitive agreement for an all-cash purchase payable at closing, subject to customary adjustments.
- Halda’s HLD-0915, an oral first-in-class RIPTAC for metastatic castration-resistant prostate cancer, showed tolerability with PSA declines and RECIST responses in early Phase 1/2 data.
- The RIPTAC mechanism links androgen receptor and BRD4 to selectively disable BRD4 in cancer cells, with preclinical models showing tumor shrinkage and PSA reductions.
- Johnson & Johnson forecasts about a $0.15 dilution to adjusted earnings per share in 2026 due to short-term financing and a one-time charge related to Halda employee equity at closing.
- The deal remains subject to conditions including expiration of the Hart-Scott-Rodino waiting period, the companies will operate separately until closing, and Centerview Partners and Goodwin Procter are advising Halda.